Boots and Upjohn trade -- an NSAID for E-Mycin
Boots announced it has revised an existing licensing agreement to give Upjohn exclusive U.S. marketing rights to the nonsteroidal anti-inflammatory flurbiprofen (Upjohn's tradename Ansaid). The exclusive rights exclude topical ophthalmic uses. In exchange, Boots receives U.S. marketing rights to Upjohn's E-Mycin (erythromycin) and "other financial adjustments".
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.